Use of reperfusion therapies in elderly patients with acute myocardial infarction

Drugs and Aging

Volumn 18, Issue 8, 2001, Pages 587-596

  Angeja, B G ^a   Gibson, C M ^b   Chin, R ^c   Canto, J G ^d   Barron, H V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG EFFICACY; EARLY DIAGNOSIS; ELDERLY CARE; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE REPERFUSION; HIGH RISK POPULATION; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0034866698     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118080-00003     Document Type: Review

References (50)

1. Management and outcome of acute myocardial infarction in older patients in the thrombolytic era
2. The delay to thrombolysis: An analysis of hospital and patient characteristics
3. Age and outcome with contemporary thrombolytic therapy: Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries trial
4. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials)
5. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain
6. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction
7. Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: Results from GUSTO-I
8. Comparison of outcome in patients with acute myocardial infarction aged >75 years with that in younger patients
9. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41,021 patients
10. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
11. How should age affect management of acute myocardial infarction? A prospective cohort study
12. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction
13. Use of reperfusion therapy for acute myocardial infarction in the United States: Data from the National Registry of Myocardial Infarction 2
14. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction
15. The TTOPP study: Lessons from an aborted trial
16. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
17. Thrombolytic therapy in the elderly
18. Acute MI in the elderly: Choosing the best revascularization method: Risks and benefits of thrombolysis, angioplasty, and bypass surgery
19. ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
20. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
21. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction
22. The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: Results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study
23. Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries
24. Thrombolysis-related intracranial hemorrhage: A radiographic analysis of 244 cases from the GUSTO-I trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
25. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction
26. The exclusion of the elderly and women from clinical trials in acute myocardial infarction
27. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: A population-based comparison
28. Improved outcome of elderly patients (> 75 years of age) with acute myocardial infarction from 1981-1983 to 1992-1994 in Israel: The SPRINT and Thrombolytic Survey Groups. Secondary Prevention Reinfarction Israel Nifedipine Trial
29. Improvement in long-term prognosis of elderly patients with acute myocardial infarction after the introduction of intravenous thrombolytic therapy
30. Long-term survival after development of acute myocardial infarction has improved after a more widespread use of thrombolysis and aspirin
31. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years
32. Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator
33. Thrombolytic therapy in older patients
34. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The Primary Angioplasty in Myocardial Infarction (PAMI) trial
35. Effect of age on outcome with primary angioplasty versus thrombolysis
36. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction
37. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction a report from the Second National Registry of Myocardial Infarction (NRMI-2)
38. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients
39. Primary angioplasty for acute myocardial infarction in the elderly
40. Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction)
41. Delayed thrombolytic treatment of older patients with acute myocardial infarction
42. Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: Analysis of the cooperative cardiovascular project
43. Time from symptom onset to treatment and outcomes after thrombolytic therapy
44. Effect on outcome of the presence or absence of chest pain at initiation of recombinant tissue plasminogen activator therapy in acute myocardial infarction
45. Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction
46. A comparison of intracranial hemorrhage rates in patients treated with rt-PA and tPA-TNK: Impact of gender, age and low body weight
47. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
48. Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: The GUSTO-I angiographic experience
49. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: Importance of microvascular reperfusion injury on clinical outcome